Marksans Pharma Ltd. — Earnings Release 2025

May 19, 2025

==> picture [47 x 46] intentionally omitted <==

==> picture [86 x 18] intentionally omitted <==

==> picture [111 x 18] intentionally omitted <==

Date : May 19, 2025

BSE Limited Corporate Relation Department Phiroze Jeejeeboi Towers, Dalal Street, Mumbai - 400001. Scrip Code: 524404

National Stock Exchange of India Limited Listing Department Exchange Plaza, C-1, Block-G, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051. Symbol: MARKSANS

Sub: Press Release

Dear Sir/Madam,

Kindly find enclosed herewith a Press Release in relation to the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2025.

Further, as per Regulation 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the said press release will also be available on the website of the Company i.e., https://www.marksanspharma.com/press-release.html.

We request you to take the aforesaid on record.

Thanking You.

Yours faithfully,

For Marksans Pharma Limited

Digitally signed by H H PANIGRAHI PANIGRAHI Date: 2025.05.19 19:54:38 +05'30'

Harshavardhan Panigrahi Company Secretary

Encl: As above

==> picture [5 x 74] intentionally omitted <==

==> picture [72 x 16] intentionally omitted <==

==> picture [93 x 16] intentionally omitted <==

==> picture [431 x 33] intentionally omitted <==

==> picture [343 x 61] intentionally omitted <==

Q4 & FY25 Financial Results

All-time high annual revenue and profits, with revenue and PAT growth of ~21% YoY

Mumbai, May 19, 2025 – Marksans Pharma Ltd. (NSE: MARKSANS; BSE Code: 524404) reported the financial results today for the quarter and year ended March 31, 2025.

Mark Saldanha, Managing Director of the Company said “We are pleased to announce another year of robust performance; we have achieved highest ever annual revenues and profits. In FY25, we witnessed strong performance across all our markets, the US market has been a key growth driver with 35% YoY increase in revenue. Our OTC segment’s performance is at all-time high, crossing INR 2000 Crs in revenue, a testament to our focus and execution on expanding the OTC product pipeline. Looking forward, we continue to strengthen our foundation by increasing the capacity and strengthening our product pipeline. We are optimistic about building on this momentum and create more value for our stakeholders in the coming years.”

Q4FY25 Financial Highlights

• Operating revenue stood at Rs. 708.5 cr., up by 26.5% YoY driven growth across key markets, led by US region

• Gross profit stood at Rs. 383.2 cr., up by 32.1% YoY, with a gross margin expansion of 228 bps YoY to 54.1%. Growth is attributed to softening of raw material prices and a better product mix.

• EBITDA stood at Rs. 125.8 cr. up by 14.7% YoY, with a margin of 17.8%

• EPS is at Rs. 2.0, an increase of 15.7%

FY25 Financial Highlights

• Operating revenue stood at Rs. 2,622.8 cr., up by 20.5% YoY driven by growth across all markets o US business grew by 34.7% YoY

• UK & Europe grew by 9.2% YoY

• Australia & New Zealand grew by 15.5% YoY

• Gross profit came in at Rs. 1,479.1 cr., up by 29.8% YoY, with a gross margin of 56.4%

• EBITDA stood at Rs. 528.6 cr., up by 15.3%, with an EBITDA margin of 20.2%

• EPS grew by 21.3% YoY to Rs. 8.4

Business Highlights

US Market

• US & North America Formulation business grew 34.7% YoY to Rs. 1,236.6 cr. in FY25

• Commercialized 58 products/SKUs | Products in pipeline 79 products

||UK and Europe Market
▪
Revenue from the UK & Europe Formulation business in FY25 stood at Rs. 1,029.8 cr., registering a growth
of 9.2% YoY.
▪ Approved 12 products | Filed 18 products during the year
Australia and New Zealand Market
▪ Australia and New Zealand business reported revenue of Rs. 252.8 cr. in FY25, an increase of 15.5% YoY
▪ Approved 3 products | Filed 3 products during the year
RoW Market
▪ RoW business reported revenue of Rs. 103.7 cr. in FY25, an increase of 6.4% YoY
Other Highlights
▪ In FY25, the capex incurred was Rs. 172.9 cr. Capex investments are in line with our plan for scaling the
acquired manufacturing unit in Goa which will drive our future growth.
▪ Cash Balance as of 31stMarch 2025 stood at Rs. 704.2 cr.
▪ Working capital cycle ~127 days for FY25
▪ In FY25, Net Cash from Operations was at Rs 206.7 cr.
▪ Research & Development (R&D) for FY25 was Rs. 57.9 cr., 2.2% of consolidated revenue.
Business Performance
Consolidated profit and loss statement:|UK and Europe Market
▪
Revenue from the UK & Europe Formulation business in FY25 stood at Rs. 1,029.8 cr., registering a growth
of 9.2% YoY.
▪ Approved 12 products | Filed 18 products during the year
Australia and New Zealand Market
▪ Australia and New Zealand business reported revenue of Rs. 252.8 cr. in FY25, an increase of 15.5% YoY
▪ Approved 3 products | Filed 3 products during the year
RoW Market
▪ RoW business reported revenue of Rs. 103.7 cr. in FY25, an increase of 6.4% YoY
Other Highlights
▪ In FY25, the capex incurred was Rs. 172.9 cr. Capex investments are in line with our plan for scaling the
acquired manufacturing unit in Goa which will drive our future growth.
▪ Cash Balance as of 31stMarch 2025 stood at Rs. 704.2 cr.
▪ Working capital cycle ~127 days for FY25
▪ In FY25, Net Cash from Operations was at Rs 206.7 cr.
▪ Research & Development (R&D) for FY25 was Rs. 57.9 cr., 2.2% of consolidated revenue.
Business Performance
Consolidated profit and loss statement:|UK and Europe Market
▪
Revenue from the UK & Europe Formulation business in FY25 stood at Rs. 1,029.8 cr., registering a growth
of 9.2% YoY.
▪ Approved 12 products | Filed 18 products during the year
Australia and New Zealand Market
▪ Australia and New Zealand business reported revenue of Rs. 252.8 cr. in FY25, an increase of 15.5% YoY
▪ Approved 3 products | Filed 3 products during the year
RoW Market
▪ RoW business reported revenue of Rs. 103.7 cr. in FY25, an increase of 6.4% YoY
Other Highlights
▪ In FY25, the capex incurred was Rs. 172.9 cr. Capex investments are in line with our plan for scaling the
acquired manufacturing unit in Goa which will drive our future growth.
▪ Cash Balance as of 31stMarch 2025 stood at Rs. 704.2 cr.
▪ Working capital cycle ~127 days for FY25
▪ In FY25, Net Cash from Operations was at Rs 206.7 cr.
▪ Research & Development (R&D) for FY25 was Rs. 57.9 cr., 2.2% of consolidated revenue.
Business Performance
Consolidated profit and loss statement:|UK and Europe Market
▪
Revenue from the UK & Europe Formulation business in FY25 stood at Rs. 1,029.8 cr., registering a growth
of 9.2% YoY.
▪ Approved 12 products | Filed 18 products during the year
Australia and New Zealand Market
▪ Australia and New Zealand business reported revenue of Rs. 252.8 cr. in FY25, an increase of 15.5% YoY
▪ Approved 3 products | Filed 3 products during the year
RoW Market
▪ RoW business reported revenue of Rs. 103.7 cr. in FY25, an increase of 6.4% YoY
Other Highlights
▪ In FY25, the capex incurred was Rs. 172.9 cr. Capex investments are in line with our plan for scaling the
acquired manufacturing unit in Goa which will drive our future growth.
▪ Cash Balance as of 31stMarch 2025 stood at Rs. 704.2 cr.
▪ Working capital cycle ~127 days for FY25
▪ In FY25, Net Cash from Operations was at Rs 206.7 cr.
▪ Research & Development (R&D) for FY25 was Rs. 57.9 cr., 2.2% of consolidated revenue.
Business Performance
Consolidated profit and loss statement:|UK and Europe Market
▪
Revenue from the UK & Europe Formulation business in FY25 stood at Rs. 1,029.8 cr., registering a growth
of 9.2% YoY.
▪ Approved 12 products | Filed 18 products during the year
Australia and New Zealand Market
▪ Australia and New Zealand business reported revenue of Rs. 252.8 cr. in FY25, an increase of 15.5% YoY
▪ Approved 3 products | Filed 3 products during the year
RoW Market
▪ RoW business reported revenue of Rs. 103.7 cr. in FY25, an increase of 6.4% YoY
Other Highlights
▪ In FY25, the capex incurred was Rs. 172.9 cr. Capex investments are in line with our plan for scaling the
acquired manufacturing unit in Goa which will drive our future growth.
▪ Cash Balance as of 31stMarch 2025 stood at Rs. 704.2 cr.
▪ Working capital cycle ~127 days for FY25
▪ In FY25, Net Cash from Operations was at Rs 206.7 cr.
▪ Research & Development (R&D) for FY25 was Rs. 57.9 cr., 2.2% of consolidated revenue.
Business Performance
Consolidated profit and loss statement:|
|---|---|---|---|---|---|
||Particulars
Q4FY25
Q4FY24
Q3FY25
YoY||QoQ|FY25
FY24|YoY|
||Operating Revenue
708.5
560.0
681.8
26.5%||3.9%|2,622.8
2,177.4|20.5%|
||Gross Profit
383.2
290.2
383.5
32.1%||-0.1%|1,479.1
1,139.3|29.8%|
||Gross margin
54.1%
51.8%
56.2%
228 bps||-215 bps|56.4%
52.3%|407 bps|
||EBITDA
125.8
109.6
138.8
14.7%||-9.4%|528.6
458.6|15.3%|
||EBITDA Margin
17.8%
19.6%
20.4%
-183 bps||-260 bps|20.2%
21.1%|-91 bps|
||PAT
90.7
77.6
105.1
16.9%||-13.6%|382.6
314.9|21.5%|
||Net Margin
12.5%
13.5%
14.8%
-95 bps||-229 bps|14.2%
14.1%|7 bps|
||EPS(Rs.)
2.0
1.7
2.3
15.7%||-13.5%|8.4
6.9|21.3%|
||All figures in Rs. Cr. unless otherwise stated
Business-wise performance:|||||
||Particulars|Q4FY25
Q4FY24
YoY
Mix|FY25|FY24
YoY|Mix|
||US & North America|328.6
245.0
34.1%
46.4%|1,236.6|918.1
34.7%|47.1%|
||UK and Europe|274.1
232.8
17.7%
38.7%|1,029.8|943.0
9.2%|39.3%|
||Australia & NZ|76.5
63.3
20.9%
10.8%|252.8|218.8
15.5%|9.6%|
||Rest of World (ROW)|29.3
18.9
55.0%
4.1%|103.7|97.4
6.4%|4.0%|
||Revenue from
operations|708.5
560.0
26.5%
100.0%|2,622.8|2,177.4
20.5%|100.0%|
||All figures in Rs. Cr. unless otherwise stated|||||

Earnings Conference Call:

There will be an Earnings conference call at 5.00 pm IST on May 20, 2025, during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at www.marksanspharma.com.

will discuss the financial performance and take questions. A transcript of the conference call will be available at www.marksanspharma.com.	will discuss the financial performance and take questions. A transcript of the conference call will be available at www.marksanspharma.com.
Date and Time May 20, 2025, at 5.00 pm IST
Diamond pass linkLink
Primary Access Numbers +91 22 6280 1146, +91 22 7115 8047
International Toll-Free Numbers US: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 Australia: 1800053698

About Marksans Pharma Ltd

Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological and Anti-allergies. The company is marketing these products globally.

Disclaimer

Certain statements in this press release concerning our future growth prospects may be forward looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; the extent and duration of the effects of the COVID-19 pandemic; litigation and investigations; business development transactions; economic conditions; and changes in laws and regulations, including health care reform. The company undertakes no duty to update forward-looking statements except as required by applicable law.

Contact Information	Registered Office
Jitendra Sharma, CFO	11th Floor, "GRANDEUR”
Marksans Pharma Ltd	Off Veera Desai Extension Road
Tel: +91 022 40012000	Oshiwara, Andheri West
jitendra@marksanspharma.com	Mumbai, Maharashtra, 400 053
	Telephone: +91 224001 2000
	Fax: +91 224001 2011
	CIN: L24110MH1992PLC066364
	ISIN: INE750C01026
	NSE Code: MARKSANS
	BSE CODE: 524404
	Website:http://www.marksanspharma.com